After the country was liberated, the population was treated for yaws by injections of arsenic, of which there was a great shortage, so only those with stage 1 were treated. Eradication
A series of WHO yaws control efforts, which began shortly after creation of the WHO in 1948, succeeded in eradicating the disease locally from many countries, but have not lasted long enough to eradicate it globally. The Global Control of Treponematoses (TCP) programme by the WHO and the UNICEF launched in 1952 and continued until 1964. A 1953 questionnaire-based estimate was that there were 50–150 million yaws cases in 90 countries. The global prevalence of yaws and the other endemic treponematoses, bejel and pinta, was reduced by the Global Control of Treponematoses (TCP) programme between 1952 and 1964 from about 50 million cases to about 2.5 million (a 95% reduction). However, "premature integration of yaws and other endemic treponematoses activities into weak primary health-care systems, and the dismantling of the vertical eradication programmes after 1964, led to the failure to finish with the remaining 5% of cases" and led to a resurgence of yaws in the 1970s, with the largest number of case found in the Western Africa region. Following the cessation of this program, resources, attention and commitment for yaws gradually disappeared and yaws remained at a low prevalence in parts of Asia, Africa, and the Americas with sporadic outbreaks.
Dysgammaglobulinemia is a type of immune disorder characterized by a reduction in some types of gamma globulins, resulting in heightened susceptibility to some infectious diseases where primary immunity is antibody based.It is distinguished from hypogammaglobulinemia, which is a reduction in all types of gamma globulins.Hyper IgM syndrome can be considered a form of dysgammaglobulinemia, because it results from a failure of transformation from IgM production to production of other antibodies, and so the condition can be interpreted as a reduction of the other types. See also
Immunodeficiency

References
Further reading
Raif S. Geha et al. : "Hyper Immunoglobulin M Immunodeficiency (Dysgammaglobulinemia)", Journal of Clinical Investigation, 1979 August; 64(2): 385–391, doi:10.1172/JCI109473. Accessed 2009-07-17. Andre Cruchaud et al. : "The site of synthesis of the 19S T-globulins in dysgammaglobulinemia" (1962). Accessed 2009-07-17. == External links ==